166 related articles for article (PubMed ID: 29552747)
21. Resistance to human immunodeficiency virus type 1 (HIV-1) generated by lentivirus vector-mediated delivery of the CCR5{Delta}32 gene despite detectable expression of the HIV-1 co-receptors.
Jin Q; Marsh J; Cornetta K; Alkhatib G
J Gen Virol; 2008 Oct; 89(Pt 10):2611-2621. PubMed ID: 18796731
[TBL] [Abstract][Full Text] [Related]
22. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction.
Liang M; Kamata M; Chen KN; Pariente N; An DS; Chen IS
J Gene Med; 2010 Mar; 12(3):255-65. PubMed ID: 20186995
[TBL] [Abstract][Full Text] [Related]
24. Restriction of HIV type 1 infection in macrophages heterozygous for a deletion in the CC-chemokine receptor 5 gene.
Ometto L; Zanchetta M; Cabrelle A; Esposito G; Mainardi M; Chieco-Bianchi L; De Rossi A
AIDS Res Hum Retroviruses; 1999 Nov; 15(16):1441-52. PubMed ID: 10555107
[TBL] [Abstract][Full Text] [Related]
25. A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model.
Shimizu S; Hong P; Arumugam B; Pokomo L; Boyer J; Koizumi N; Kittipongdaja P; Chen A; Bristol G; Galic Z; Zack JA; Yang O; Chen IS; Lee B; An DS
Blood; 2010 Feb; 115(8):1534-44. PubMed ID: 20018916
[TBL] [Abstract][Full Text] [Related]
26. Specific transduction of HIV-susceptible cells for CCR5 knockdown and resistance to HIV infection: a novel method for targeted gene therapy and intracellular immunization.
Anderson JS; Walker J; Nolta JA; Bauer G
J Acquir Immune Defic Syndr; 2009 Oct; 52(2):152-61. PubMed ID: 19593160
[TBL] [Abstract][Full Text] [Related]
27. Foamy virus vectors expressing anti-HIV transgenes efficiently block HIV-1 replication.
Taylor JA; Vojtech L; Bahner I; Kohn DB; Laer DV; Russell DW; Richard RE
Mol Ther; 2008 Jan; 16(1):46-51. PubMed ID: 17955023
[TBL] [Abstract][Full Text] [Related]
28. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy.
Li MJ; Kim J; Li S; Zaia J; Yee JK; Anderson J; Akkina R; Rossi JJ
Mol Ther; 2005 Nov; 12(5):900-9. PubMed ID: 16115802
[TBL] [Abstract][Full Text] [Related]
29. Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance.
Anderson J; Banerjea A; Akkina R
Oligonucleotides; 2003; 13(5):303-12. PubMed ID: 15000821
[TBL] [Abstract][Full Text] [Related]
30. Analyses of anti-HIV type 1 activity of a small CCR5 peptide antagonist.
Wang FY; He SY; Zhang ZJ; He LF; Chen XW; Teng T
AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1111-5. PubMed ID: 21375388
[TBL] [Abstract][Full Text] [Related]
31. Inducible expression of the deltaNGFr/F12Nef fusion protein as a new tool for anti-human immunodeficiency virus type 1 gene therapy.
Muratori C; Schiavoni I; Melucci-Vigo G; Olivetta E; Santarcangelo AC; Pugliese K; Verani P; Federico M
Hum Gene Ther; 2002 Sep; 13(14):1751-66. PubMed ID: 12396627
[TBL] [Abstract][Full Text] [Related]
32. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
[TBL] [Abstract][Full Text] [Related]
33. The Effects of the Recombinant CCR5 T4 Lysozyme Fusion Protein on HIV-1 Infection.
Jin Q; Chen H; Wang X; Zhao L; Xu Q; Wang H; Li G; Yang X; Ma H; Wu H; Ji X
PLoS One; 2015; 10(7):e0131894. PubMed ID: 26154172
[TBL] [Abstract][Full Text] [Related]
34. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
35. Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.
Zhou J; Satheesan S; Li H; Weinberg MS; Morris KV; Burnett JC; Rossi JJ
Chem Biol; 2015 Mar; 22(3):379-90. PubMed ID: 25754473
[TBL] [Abstract][Full Text] [Related]
36. Effective suppression of human immunodeficiency virus type 1 through a combination of short- or long-hairpin RNAs targeting essential sequences for retroviral integration.
Nishitsuji H; Kohara M; Kannagi M; Masuda T
J Virol; 2006 Aug; 80(15):7658-66. PubMed ID: 16840344
[TBL] [Abstract][Full Text] [Related]
37. Silencing of HIV-1 with RNA interference: a multiple shRNA approach.
ter Brake O; Konstantinova P; Ceylan M; Berkhout B
Mol Ther; 2006 Dec; 14(6):883-92. PubMed ID: 16959541
[TBL] [Abstract][Full Text] [Related]
38. The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline.
Kramer VG; Hassounah S; Colby-Germinario SP; Oliveira M; Lefebvre E; Mesplède T; Wainberg MA
J Antimicrob Chemother; 2015 Mar; 70(3):750-6. PubMed ID: 25433008
[TBL] [Abstract][Full Text] [Related]
39. Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32.
Henrich TJ; Hanhauser E; Hu Z; Stellbrink HJ; Noah C; Martin JN; Deeks SG; Kuritzkes DR; Pereyra F
AIDS; 2015 May; 29(8):867-76. PubMed ID: 25730507
[TBL] [Abstract][Full Text] [Related]
40. Endogenous MCM7 microRNA cluster as a novel platform to multiplex small interfering and nucleolar RNAs for combinational HIV-1 gene therapy.
Chung J; Zhang J; Li H; Ouellet DL; DiGiusto DL; Rossi JJ
Hum Gene Ther; 2012 Nov; 23(11):1200-8. PubMed ID: 22834872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
